- Home
- NEN vs TSHA Comparison
NEN vs TSHA Comparison
Compare NEN & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEN
- TSHA
- Stock Information
- Founded
- NEN 1977
- TSHA 2019
- Country
- NEN United States
- TSHA United States
- Employees
- NEN N/A
- TSHA N/A
- Industry
- NEN Building operators
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- NEN Real Estate
- TSHA Health Care
- Exchange
- NEN Nasdaq
- TSHA Nasdaq
- Market Cap
- NEN 278.3M
- TSHA 262.4M
- IPO Year
- NEN N/A
- TSHA 2020
- Fundamental
- Price
- NEN N/A
- TSHA $1.24
- Analyst Decision
- NEN
- TSHA Strong Buy
- Analyst Count
- NEN 0
- TSHA 8
- Target Price
- NEN N/A
- TSHA $6.63
- AVG Volume (30 Days)
- NEN 906.0
- TSHA 2.4M
- Earning Date
- NEN 01-01-0001
- TSHA 05-13-2025
- Dividend Yield
- NEN 6.25%
- TSHA N/A
- EPS Growth
- NEN 87.60
- TSHA N/A
- EPS
- NEN 4.46
- TSHA N/A
- Revenue
- NEN $81,814,652.00
- TSHA $8,333,000.00
- Revenue This Year
- NEN N/A
- TSHA N/A
- Revenue Next Year
- NEN N/A
- TSHA N/A
- P/E Ratio
- NEN $17.78
- TSHA N/A
- Revenue Growth
- NEN 8.57
- TSHA N/A
- 52 Week Low
- NEN $67.50
- TSHA $1.05
- 52 Week High
- NEN $84.00
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- NEN 51.34
- TSHA 40.35
- Support Level
- NEN $76.76
- TSHA $1.05
- Resistance Level
- NEN $80.00
- TSHA $1.36
- Average True Range (ATR)
- NEN 0.34
- TSHA 0.17
- MACD
- NEN -0.09
- TSHA -0.01
- Stochastic Oscillator
- NEN 53.88
- TSHA 25.68
About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.